Melatonin and its atheroprotective effects: A review

Molecular and Cellular Endocrinology

Volumn 382, Issue 2, 2014, Pages 926-937

  Favero, Gaia ^a   Rodella, Luigi Fabrizio ^a   Reiter, Russel J ^b   Rezzani, Rita ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Atherosclerosis; Melatonin; Oxidative stress

Indexed keywords

ARGININE; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; DIET SUPPLEMENTATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; DRUG TARGETING; HORMONE ACTION; HUMAN; INFLAMMATION; METABOLIC SYNDROME X; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; VASCULAR DISEASE; VASOCONSTRICTION; VASODILATATION;

ATHEROSCLEROSIS; MELATONIN; OXIDATIVE STRESS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; ATHEROSCLEROSIS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; MELATONIN; MITOCHONDRIA; OXIDATIVE STRESS; PLAQUE, ATHEROSCLEROTIC; REACTIVE OXYGEN SPECIES; RECEPTORS, MELATONIN; SIGNAL TRANSDUCTION;

EID: 84890028007     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.11.016     Document Type: Review

References (176)

1. Abuja P.M., Liebmann P., Hayn M., Schauenstein K., Esterbauer H. Antioxidant role of melatonin in lipid peroxidation of human LDL. FEBS Lett. 1997, 413:289-293.
2. Acuña-Castroviejo D., Reiter R.J., Menéndez-Peláez A., Pablos M.I., Burgos A. Characterization of high-affinity melatonin binding sites in purified cell nuclei of rat liver. J. Pineal Res. 1994, 16:100-112.
3. Agil A., Navarro-Alarcón M., Ruiz R., Abuhamadah S., El-Mir M.Y., Vázquez G.F. Beneficial effects of melatonin on obesity and lipid profile in young Zucker diabetic fatty rats. J. Pineal Res. 2011, 50:207-212.
4. Arendt J., Skene D.J. Melatonin as a chronobiotic. Sleep Med. Rev. 2005, 9:25-39.
5. Badimón L., Vilahur G., Padró T. Lipoproteins, platelets and atherothrombosis. Rev. Esp. Cardiol. 2009, 62:1161-1178.
6. Badimon L., Vilahur G., Padro T. Nutraceuticals and atherosclerosis: human trials. Cardiovasc. Ther. 2010, 28:202-215.
7. Bai Y., Sun L., Yang T., Sun K., Chen J., Hui R. Increase in fasting vascular endothelial function after short-term oral l-arginine is effective when baseline flow-mediated dilation is low: a meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 2009, 89:77-84.
8. Balakrishnan K.R., Kuruvilla S., Srinivasan A., Sehgal P.K. Images in cardiovascular medicine. Electron microscopic insights into the vascular biology of atherosclerosis: study of coronary endarterectomy specimens. Circulation 2007, 115:388-390.
9. Ballinger S.W., Patterson C., Knight-Lozano C.A., Burow D.L., Conklin C.A., Hu Z., Reuf J., Horaist C., Lebovitz R., Hunter G.C., McIntyre K., Runge M.S. Mitochondrial integrity and function in atherogenesis. Circulation 2002, 106:544-549.
10. Becker-André M., Wiesenberg I., Schaeren-Wiemers N., André E., Missbach M., Saurat J.H., Carlberg C. Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily. J. Biol. Chem. 1994, 269:28531-28534.
11. Bedrosian T.A., Herring K.L., Walton J.C., Fonken L.K., Weil Z.M., Nelson R.J. Evidence for feedback control of pineal melatonin secretion. Neurosci. Lett. 2013, 542:123-125.
12. Benítez-King G., Antón-Tay F. Calmodulin mediates melatonin cytoskeletal effects. Experientia 1993, 49:635-641.
13. Bobryshev Y.V. Monocyte recruitment and foam cell formation in atherosclerosis. Micron 2006, 37:208-222.
14. Bobryshev Y.V., Killingsworth M.C., Lord R.S., Grabs A.J. Matrix vesicles in the fibrous cap of atherosclerotic plaque: possible contribution to plaque rupture. J. Cell. Mol. Med. 2008, 12:2073-2082.
15. Bode-Böger S.M., Muke J., Surdacki A., Brabant G., Böger R.H., Frölich J.C. Oral l-arginine improves endothelial function in healthy individuals older than 70years. Vasc. Med. 2003, 8:77-81.
16. Bonomini F., Tengattini S., Fabiano A., Bianchi R., Rezzani R. Atherosclerosis and oxidative stress. Histol. Histopathol. 2008, 23:381-390.
17. Borucki K., Aronica S., Starke I., Luley C., Westphal S. Addition of 2.5g l-arginine in a fatty meal prevents the lipemia-induced endothelial dysfunction in healthy volunteers. Atherosclerosis 2009, 205:251-254.
18. Bubenik G.A. Gastrointestinal melatonin: localization, function, and clinical relevance. Dig. Dis. Sci. 2002, 47:2336-2348.
19. Businaro R., Tagliani A., Buttari B., Profumo E., Ippoliti F., Di Cristofano C., Capoano R., Salvati B., Riganò R. Cellular and molecular players in the atherosclerotic plaque progression. Ann. N. Y. Acad. Sci. 2012, 1262:134-141.
20. Cardinali D.P., Cano P., Jiménez-Ortega V., Esquifino A.I. Melatonin and the metabolic syndrome: physiopathologic and therapeutical implications. Neuroendocrinology 2011, 93:133-142.
21. Carrillo-Vico A., Reiter R.J., Lardone P.J., Herrera J.L., Fernández-Montesinos R., Guerrero J.M., Pozo D. The modulatory role of melatonin on immune responsiveness. Curr. Opin. Invest. Drugs 2006, 7:423-431.
22. Chan T.Y., Tang P.L. Effect of melatonin on the maintenance of cholesterol homeostasis in the rat. Endocr. Res. 1995, 21:681-696.
23. Chen J., Mehta J.L., Haider N., Zhang X., Narula J., Li D. Role of caspases in Ox-LDL-induced apoptotic cascade in human coronary artery endothelial cells. Circ. Res. 2004, 94:370-376.
24. Chisolm G.M. Antioxidants and atherosclerosis: a current assessment. Clin. Cardiol. 1991, 14:125-130.
25. Congiu T., Schembri L., Tozzi M., Guasti L., Maio R.C., Cosentino M., Marino F. Scanning electron microscopy examination of endothelium morphology in human carotid plaques. Micron 2010, 41:532-536.
26. Dauchy R.T., Blask D.E., Sauer L.A., Davidson L.K., Krause J.A., Smith L.C., Dauchy E.M. Physiologic melatonin concentration, omega-3 fatty acids, and conjugated linoleic acid inhibit fatty acid transport in rodent hind limb skeletal muscle in vivo. Comp. Med. 2003, 53:186-190.
27. Delgado-Roche L., Martínez-Sánchez G., Re L. Ozone oxidative preconditioning prevents atherosclerosis development in New Zealand white rabbits. J. Cardiovasc. Pharmacol. 2013, 61:160-165.
28. Dellegar S.M., Murphy S.A., Bourne A.E., DiCesare J.C., Purser G.H. Identification of the factors affecting the rate of deactivation of hypochlorous acid by melatonin. Biochem. Biophys. Res. Commun. 1999, 257:431-439.
29. Dell'Orbo C., Quacci D., Raspanti M., Congiu T., Reguzzoni M., Protasoni M. Atherosclerotic alterations in human carotid observed by scanning electron microscopy. Ital. J. Anat. Embryol. 2010, 115:53-58.
30. Dominguez-Rodriguez A., Abreu-Gonzalez P., Reiter R.J. Clinical aspects of melatonin in the acute coronary syndrome. Curr. Vasc. Pharmacol. 2009, 7:367-373.
31. Dubocovich M.L., Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005, 27:101-110.
32. Dubocovich M.L., Delagrange P., Krause D.N., Sugden D., Cardinali D.P., Olcese J. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol. Rev. 2010, 62:343-380.
33. Duchen M.R. Mitochondria in health and disease: perspectives on a new mitochondrial biology. Mol. Aspects Med. 2004, 25:365-451.
34. Duell P.B., Wheaton D.L., Shultz A., Nguyen H. Inhibition of LDL oxidation by melatonin requires supraphysiologic concentrations. Clin. Chem. 1998, 44:1931-1936.
35. Duguid J.B. Pathogenesis of atherosclerosis. Lancet 1949, 2:925-927.
36. Duran M.C., Mas S., Martin-Ventura J.L., Meilhac O., Michel J.B., Gallego-Delgado J., Lázaro A., Tuñon J., Egido J., Vivanco F. Proteomic analysis of human vessels: application to atherosclerotic plaques. Proteomics 2003, 3:973-978.
37. Ekmekcioglu C., Haslmayer P., Philipp C., Mehrabi M.R., Glogar H.D., Grimm M., Thalhammer T., Marktl W. 24h Variation in the expression of the mt1 melatonin receptor subtype in coronary arteries derived from patients with coronary heart disease. Chronobiology 2001, 18:973-985.
38. Ekmekcioglu C., Thalhammer T., Humpeler S., Mehrabi M.R., Glogar H.D., Hölzenbein T., Markovic O., Leibetseder V.J., Strauss-Blasche G., Marktl W. The melatonin receptor subtype MT2 is present in the human cardiovascular system. J. Pineal Res. 2003, 35:40-44.
39. Facciolá G., Hidestrand M., von Bahr C., Tybring G. Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes. Eur. J. Clin. Pharmacol. 2001, 56:881-888.
40. Favero G., Lonati C., Giugno L., Castrezzati S., Rodella L.F., Rezzani R. Obesity-related dysfunction of the aorta and prevention by melatonin treatment in ob/ob mice. Acta Histochem. 2013, [Epub ahead of print].
41. Ferguson S.A., Rajaratnam S.M., Dawson D. Melatonin agonists and insomnia. Expert Rev. Neurother. 2010, 10:305-318.
42. Finsterer J. Is atherosclerosis a mitochondrial disorder?. Vasa 2007, 36:229-240.
43. Galano A., Tan D.X., Reiter R.J. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J. Pineal Res. 2011, 51:1-16.
44. Galano A., Tan D.X., Reiter R.J. On the free radical scavenging activities of melatonin's metabolites. AFMK and AMK. J. Pineal Res. 2013, 54:245-257.
45. Girouard H., Chulak C., Lejossec M., Lamontagne D., de Champlain J. Vasorelaxant effects of the chronic treatment with melatonin on mesenteric artery and aorta of spontaneously hypertensive rats. J. Hypertens. 2001, 19:1369-1377.
46. Gomez F.J., Raba J., Cerutti M.F. Monitoring melatonin and its isomer in Vitis vinifera cv. Malbec by UHPLC-MS/MS from grape to bottle. J. Pineal Res. 2012, 52:349-355.
47. Grace M.S., Cahill G.M., Besharse J.C. Melatonin, deacetylation: retinal vertebrate class distribution and Xenopus laevis tissue distribution. Brain Res. 1991, 13:56-63.
48. Griendling K.K., Sorescu D., Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res. 2000, 86:494-501.
49. Guardiola-Lemaître B. Toxicology of melatonin. J. Biol. Rhythms 1997, 12:697-706.
50. Hardeland R., Poeggeler B. Non-vertebrate melatonin. J. Pineal Res. 2003, 34:233-241.
51. Hardeland R. Neurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction. ScientificWorldJournal 2012, 2012:640389.
52. Hardeland R., Reiter R.J., Poeggeler B., Tan D.X. The significance of the metabolism of the neurohormone melatonin: antioxidative protection and formation of bioactive substances. Neurosci. Biobehav. Rev. 1993, 17:347-357.
53. Hardeland R., Pandi S.R., Cardinali D.P. Melatonin. Int. J. Biochem. Cell. Biol. 2006, 38:313-316.
54. Hardeland R., Cardinali D.P., Srinivasan V., Spence D.W., Brown G.M., Pandi-Perumal S.R. Melatonin - a pleiotropic, orchestrating regulator molecule. Prog. Neurobiol. 2011, 93:350-384.
55. Hardeland R., Madrid J.A., Tan D.X., Reite R.J. Melatonin, the circadian multioscillator system and health: the need for detailed analyses of peripheral melatonin signaling. J. Pineal Res. 2012, 52:139-166.
56. Heinecke J.W. Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis 1998, 141:1-15.
57. Hennig B., Toborek M., McClain C.J. High-energy diets, fatty acids and endothelial cell function: implications for atherosclerosis. J. Am. Coll. Nutr. 2001, 20(Suppl. 2):97-105.
58. Hussein M.R., Ahmed O.G., Hassan A.F., Ahmed M.A. Intake of melatonin is associated with amelioration of physiological changes, both metabolic and morphological pathologies associated with obesity: an animal model. Int. J. Exp. Pathol. 2007, 88:19-29.
59. Iriti M., Faoro F. Bioactivity of grape chemicals for human health. Nat. Prod. Commun. 2009, 4:611-634.
60. Iriti M., Varoni E.M., Vitalini S. Melatonin in traditional Mediterranean diets. J. Pineal Res. 2010, 49:101-105.
61. James A.M., Murphy M.P. How mitochondrial damage affects cell function. J. Biomed. Sci. 2002, 9:475-487.
62. Jan J.E., Hamilton D., Seward N., Fast D.K., Freeman R.D., Laudon M. Clinical trials of controlled-release melatonin in children with sleep-wake cycle disorders. J. Pineal Res. 2000, 29:34-39.
63. Jou M.J., Peng T.I., Hsu L.F., Jou S.B., Reiter R.J., Yang C.M., Chiao C.C., Lin Y.F., Chen C.C. Visualization of melatonin's multiple mitochondrial levels of protection against mitochondrial Ca(2+)-mediated permeability transition and beyond in rat brain astrocytes. J. Pineal Res. 2010, 48:20-38.
64. Kaliora A.C., Dedoussis G.V., Schmidt H. Dietary antioxidants in preventing atherogenesis. Atherosclerosis 2006, 187:1-17.
65. Kamari Y., Cohen H., Shaish A., Bitzur R., Afek A., Shen S., Vainshtein A., Harats D. Characterisation of atherosclerotic lesions with scanning electron microscopy (SEM) of wet tissue. Diab. Vasc. Dis. Res. 2008, 5:44-47.
66. Karasek M. Melatonin, human aging, and age-related diseases. Exp. Gerontol. 2004, 39:1723-1729.
67. Karbownik M., Tan D., Manchester L.C., Reiter R.J. Renal toxicity of the carcinogen delta-aminolevulinic acid: antioxidant effects of melatonin. Cancer Lett. 2000, 161:1-7.
68. Kelly M.R., Loo G. Melatonin inhibits oxidative modification of human low-density lipoprotein. J. Pineal Res. 1997, 22:203-209.
69. Kerényi N.A., Balogh I., Somogyi E., Sótonyi P. Cytochemical investigation of acetyl-serotonin-transferase activity in the pineal gland. Cell. Mol. Biol. Incl. Cytol. Enzymol. 1979, 25:259-262.
70. Korkmaz A., Topal T., Tan D.X., Reiter R.J. Role of melatonin in metabolic regulation. Rev. Endocr. Metab. Disord. 2009, 10:261-270.
71. Kowaltowski A.J., Vercesi A.E. Mitochondrial damage induced by conditions of oxidative stress. Free Radic. Biol. Med. 1999, 26:463-471.
72. Koziróg M., Poliwczak A.R., Duchnowicz P., Koter-Michalak M., Sikora J., Broncel M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J. Pineal Res. 2011, 50:261-266.
73. Kruth H.S. Lipoprotein cholesterol and atherosclerosis. Curr. Mol. Med. 2001, 1:633-653.
74. Lamont K.T., Somers S., Lacerda L., Opie L.H., Lecour S. Is red wine a SAFE sip away from cardioprotection? Mechanisms involved in resveratrol- and melatonin-induced cardioprotection. J. Pineal Res. 2011, 50:374-380.
75. León J., Acuña-Castroviejo D., Sainz R.M., Mayo J.C., Tan D.X., Reiter R.J. Melatonin and mitochondrial function. Life Sci. 2004, 75:765-790.
76. León J., Acuña-Castroviejo D., Escames G., Tan D.X., Reiter R.J. Melatonin mitigates mitochondrial malfunction. J. Pineal Res. 2005, 38:1-9.
77. Lerner A.B. Hormonal control of pigmentation. Annu. Rev. Med. 1960, 11:187-194.
78. Little P.J., Chait A., Bobik A. Cellular and cytokine-based inflammatory processes as novel therapeutic targets for the prevention and treatment of atherosclerosis. Pharmacol. Ther. 2011, 131:255-268.
79. López A., García J.A., Escames G., Venegas C., Ortiz F., López L.C., Acuña-Castroviejo D. Melatonin protects the mitochondria from oxidative damage reducing oxygen consumption, membrane potential, and superoxide anion production. J. Pineal Res. 2009, 46:188-198.
80. Marshall K.A., Reiter R.J., Poeggeler B., Aruoma O.I., Halliwell B. Evaluation of the antioxidant activity of melatonin in vitro. Free Radic. Biol. Med. 1996, 21:307-315.
81. Martín M., Macías M., Escames G., León J., Acuña-Castroviejo D. Melatonin but not vitamins C and E maintains glutathione homeostasis in t-butyl hydroperoxide-induced mitochondrial oxidative stress. FASEB J. 2000, 14:1677-1679. Erratum in: FASEB J. 14, 2128.
82. Masana M.I., Doolen S., Ersahin C., Al-Ghoul W.M., Duckles S.P., Dubocovich M.L., Krause D.N. MT(2) melatonin receptors are present and functional in rat caudal artery. J. Pharmacol. Exp. Ther. 2002, 302:1295-1302.
83. Mauriz J.L., Collado P.S., Veneroso C., Reiter R.J., González-Gallego J. A review of the molecular aspects of melatonin's anti-inflammatory actions: recent insights and new perspectives. J. Pineal Res. 2013, 54:1-14.
84. Mayo J.C., Sainz R.M., Tan D.X., Hardeland R., Leon J., Rodriguez C., Reiter R.J. Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages. J. Neuroimmunol. 2005, 165:139-149.
85. McIntyre I.M., Norman T.R., Burrows G.D., Armstrong S.M. Human melatonin suppression by light is intensity dependent. J. Pineal Res. 1989, 9:149-156.
86. McLaren J.E., Michael D.R., Ashlin T.G., Ramji D.P. Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog. Lipid Res. 2011, 50:331-347.
87. Mercer J.R., Cheng K.K., Figg N., Gorenne I., Mahmoudi M., Griffin J., Vidal-Puig A., Logan A., Murphy M.P., Bennett M. DNA damage links mitochondrial dysfunction to atherosclerosis and the metabolic syndrome. Circ. Res. 2010, 107:1021-1031.
88. Mercolini L., Mandrioli R., Raggi M.A. Content of melatonin and other antioxidants in grape-related foodstuffs: measurement using a MEPS-HPLC-F method. J. Pineal Res. 2012, 53:21-28.
89. Montilla P.L., Vargas J.F., Túnez I.F., Muñoz de Agueda M.C., Valdelvira M.E., Cabrera E.S. Oxidative stress in diabetic rats induced by streptozotocin: protective effects of melatonin. J. Pineal Res. 1998, 25:94-100.
90. Müller-Wieland D., Behnke B., Koopmann K., Krone W. Melatonin inhibits LDL receptor activity and cholesterol synthesis in freshly isolated human mononuclear leukocytes. Biochem. Biophys. Res. Commun. 1994, 203:416-421.
91. Nakashima Y., Plump A.S., Raines E.W., Breslow J.L., Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler. Thromb. 1994, 14:133-140.
92. Nduhirabandi F., du Toit E.F., Lochner A. Melatonin and the metabolic syndrome: a tool for effective therapy in obesity-associated abnormalities?. Acta Physiol. (Oxf.) 2012, 205:209-223.
93. Nosjean O., Ferro M., Coge F., Beauverger P., Henlin J.M., Lefoulon F., Fauchere J.L., Delagrange P., Canet E., Boutin J.A. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J. Biol. Chem. 2006, 275:31311-31317.
94. Okatani Y., Wakatsuki A., Watanabe K., Ikenoue N., Fukaya T. Melatonin inhibits vasospastic action of oxidized low-density lipoprotein in human umbilical arteries. J. Pineal Res. 2000, 29:74-80.
95. Oxenkrug G.F., Summergrad P. Ramelteon attenuates age-associated hypertension and weight gain in spontaneously hypertensive rats. Ann. N. Y. Acad. Sci. 2010, 1199:114-120.
96. Pablos M.I., Agapito M.T., Gutierrez R., Recio J.M., Reiter R.J., Barlow-Walden L., Acuña-Castroviejo D., Menendez-Pelaez A. Melatonin stimulates the activity of the detoxifying enzyme glutathione peroxidase in several tissues of chicks. J. Pineal Res. 1995, 19:111-115.
97. Pablos M.I., Reiter R.J., Ortiz G.G., Guerrero J.M., Agapito M.T., Chuang J.I., Sewerynek E. Rhythms of glutathione peroxidase and glutathione reductase in brain of chick and their inhibition by light. Neurochem. Int. 1998, 32:69-75.
98. Pandi-Perumal S.R., Trakht I., Srinivasan V., Spence D.W., Maestroni G.J., Zisapel N., Cardinali D.P. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog. Neurobiol. 2008, 85:335-353.
99. Papakonstantinou E., Roth M., Karakiulakis G. Isolation and characterization of glycosaminoglycans from human atheromatous vessels. Methods Mol. Med. 2001, 52:123-136.
100. Paradies G., Petrosillo G., Paradies V., Reiter R.J., Ruggiero F.M. Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease. J. Pineal Res. 2010, 48:297-310.
101. Paredes S.D., Bejarano I., Terrón M.P., Barriga C., Reiter R.J., Rodríguez A.B. Melatonin and tryptophan counteract lipid peroxidation and modulate superoxide dismutase activity in ringdove heterophils in vivo. Effect of antigen-induced activation and age. Age (Dordr.) 2009, 31:179-188.
102. Paul P., Lahaye C., Delagrange P., Nicolas J.P., Canet E., Boutin J.A. Characterization of 2-[125I]iodomelatonin binding sites in Syrian hamster peripheral organs. J. Pharmacol. Exp. Ther. 1999, 290:334-340.
103. Perrotta I. Ultrastructural features of human atherosclerosis. Ultrastruct. Pathol. 2013, 37:43-51.
104. Pita M.L., Hoyos M., Mart-Lacave I., Osuna C., Fernández-Santos J.M., Guerrero J.M. Long-term melatonin administration increases polyunsaturated fatty acid percentage in plasma lipids of hypercholesterolemic rats. J. Pineal Res. 2002, 32:179-186.
105. Pizzarelli F., Maas R., Dattolo P., Tripepi G., Michelassi S., D'Arrigo G., Mieth M., Bandinelli S., Ferrucci L., Zoccali C. Asymmetric dimethylarginine predicts survival in the elderly. Age (Dordr.) 2013, 35:2465-2475.
106. Poon A.M., Pang S.F. 2[125I]iodomelatonin binding sites in spleens of guinea pigs. Life Sci. 1992, 50:1719-1726.
107. Prunet B., Desbazeille M., Bros A., Louche K., Delagrange P., Renard P., Casteilla L., Pénicaud L. Melatonin reduces body weight gain in Sprague Dawley rats with diet-induced obesity. Endocrinology 2003, 144:5347-5352.
108. Puddu P., Puddu G.M., Gallett iL., Cravero E., Muscari A. Mitochondrial dysfunction as an initiating event in atherogenesis: a plausible hypothesis. Cardiology 2005, 103:137-141.
109. Puddu P., Puddu G.M., Cravero E., De Pascalis S., Muscari A. The emerging role of cardiovascular risk factor-induced mitochondrial dysfunction in atherogenesis. J. Biomed. Sci. 2009, 16:112.
110. Ramakrishna A., Giridhar P., Sankar K.U., Ravishankar G.A. Melatonin and serotonin profiles in beans of Coffea species. J. Pineal Res. 2012, 52:470-476.
111. Reiter R.J. Melatonin: the chemical expression of darkness. Mol. Cell. Endocrinol. 1991, 79:153-158.
112. Reiter R.J. The melatonin rhythm: both a clock and a calendar. Experientia 1993, 49:654-664.
113. Reiter R.J., Korkmaz A. Clinical aspects of melatonin. Saudi Med. J. 2008, 29:1537-1547.
114. Reiter R.J., Tan D.X., Manchester L.C., Pilar Terron M., Flores L.J., Koppisepi S. Medical implications of melatonin: receptor-mediated and receptor-independent actions. Adv. Med. Sci. 2007, 52:11-28.
115. Reiter R.J., Tan D.X., Korkmaz A. The circadian melatonin rhythm and its modulation: possible impact on hypertension. Hypertens. 2009, Suppl. 27:17-20.
116. Reiter R.J., Tan D.X., Fuentes-Broto L. Melatonin: a multitasking molecule. Prog. Brain Res. 2010, 181:127-151.
117. Reiter R.J., Tan D.X., Paredes S.D., Fuentes-Broto L. Beneficial effects of melatonin in cardiovascular disease. Ann. Med. 2010, 42:276-285.
118. Reiter R.J., Coto-Montes A., Boga J.A., Fuentes-Broto L., Rosales-Corral S., Tan D.X. Melatonin: new applications in clinical and veterinary medicine, plant physiology and industry. Neuron. Endocrinol. Lett. 2011, 32:575-587.
119. Reiter R.J., Tan D.X., Rosales-Corral S., Manchester L.C. The universal nature, unequal distribution and antioxidant functions of melatonin and its derivatives. Mini Rev. Med. Chem. 2013, 13:373-384.
120. Rezzani R., Favero G., Stacchiotti A., Rodella L.F. Endothelial and vascular smooth muscle cell dysfunction mediated by cyclophylin A and the atheroprotective effects of melatonin. Life Sci. 2013, 92:875-882.
121. Rodella L.F., Favero G. Atherosclerosis and current antioxidant strategies for atheroprotection. Curr Trends Atherogen 2013, 1-26. InTech, Chapter 1.
122. Rodella L.F., Favero G., Rossini C., Foglio E., Reiter R.J., Rezzani R. Endothelin-1 as a potential marker of melatonin's therapeutic effects in smoking-induced vasculopathy. Life Sci. 2010, 87:558-564.
123. Rodella L.F., Filippini F., Bonomini F., Bresciani R., Reiter R.J., Rezzani R. Beneficial effects of melatonin on nicotine-induced vasculopathy. J. Pineal Res. 2010, 48:126-132.
124. Rodella L.F., Rossini C., Favero G., Foglio E., Loreto C., Rezzani R. Nicotine-induced morphological changes in rat aorta: the protective role of melatonin. Cells Tissues Organs 2012, 252-259. z(3).
125. Rodella L.F., Favero G., Foglio E., Rossini C., Castrezzati S., Lonati C., Rezzani R. Vascular endothelial cells and dysfunctions: role of melatonin. Front. Biosci. (Elite Ed) 2013, 1:119-129.
126. Ross R. Atherosclerosis is an inflammatory disease. Am. Heart J. 1999, 138:419-420.
127. Ross R., Glomset J.A. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 1973, 180:1332-1339.
128. Ross R., Glomset J.A. The pathogenesis of atherosclerosis (first of two parts). N. Engl. J. Med. 1976, 295:369-377.
129. Ross R., Glomset J.A. The pathogenesis of atherosclerosis (second of two parts). N. Engl. J. Med. 1976, 295:420-425.
130. Sae-Teaw M., Johns J., Johns N.P., Subongkot S. Serum melatonin levels and antioxidant capacities after consumption of pineapple, orange, or banana by healthy male volunteers. J. Pineal Res. 2013, 55:58-64.
131. Sartori C., Dessen P., Mathieu C., Monney A., Bloch J., Nicod P., Scherrer U., Duplain H. Melatonin improves glucose homeostasis and endothelial vascular function in high-fat diet-fed insulin-resistant mice. Endocrinology 2009, 150:5311-5317.
132. Satoh K., Matoba T., Suzuki J., O'Dell M.R., Nigro P., Cui Z., Mohan A., Pan S., Li L., Jin Z.G., Yan C., Abe J., Berk B.C. Cyclophilin A mediates vascular remodeling by promoting inflammation and vascular smooth muscle cell proliferation. Circulation 2008, 117:3088-3098.
133. Seegar H., Mueck A.O., Lippert T.H. Effect of melatonin and metabolites on copper-mediated oxidation of flow density lipoprotein. Br. J. Clin. Pharmacol. 1997, 44:283-284.
134. Simko F., Reiter R.J., Pechanova O., Paulis L. Experimental models of melatonin-deficient hypertension. Front. Biosci. 2013, 18:616-625.
135. Slominski A., Tobin D.J., Zmijewski M.A., Wortsman J., Paus R. Melatonin in the skin: synthesis, metabolism and functions. Trends Endocrinol. Metab. 2008, 19:17-22.
136. Slominski R.M., Reiter R.J., Schlabritz-Loutsevitch N., Ostrom R.S., Slominski A.T. Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol. Cell. Endocrinol. 2012, 351:152-166.
137. Sobenin I.A., Chistiakov D.A., Bobryshev Y.V., Postnov A.Y., Orekhov A.N. Mitochondrial mutations in atherosclerosis: new solutions in research and possible clinical applications. Curr. Pharm. Des. 2013, 19:5942-5953.
138. Spagnoli L.G., Bonanno E., Sangiorgi G., Mauriello A. Role of inflammation in atherosclerosis. J. Nucl. Med. 2007, 48:1800-1815.
139. Stary H.C. Lipid and macrophage accumulations in arteries of children and the development of atherosclerosis. Am. J. Clin. Nutr. 2000, 72:1297S-1306S.
140. Stary H.C., Blankenhorn D.H., Chandle rA.B., Glagov S., Insull W.J., Richardson M., Rosenfeld M.E., Schaffer S.A., Schwartz C.J., Wagner W.D., Wissler M.D. A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler. Thromb. 1992, 12:120-134.
141. Stary H.C., Chandler A.B., Glagov S., Guyton J.R., Insull W., Rosenfeld M.E., Schaffer S.A., Schwartz C.J., Wagner W.D., Wissler R.W. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis. American Heart Association. Arterioscler. Thromb. 1994, 14:840-856.
142. Stary H.C., Chandler A.B., Dinsmore R.E., Fuster V., Glagov S., Insull W., Rosenfeld M.E., Schwartz C.J., Wagner W.D., Wissler R.W. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis. American Heart Association. Circulation 1995, 92:1355-1374.
143. Stehle J.H., Saade A., Rawashdeh O., Ackermann K., Jilg A., Sebestény T., Maronde E. A survey of molecular details in the human pineal gland in the light of phylogeny, structure, function and chronobiological diseases. J. Pineal Res. 2011, 51:17-43.
144. Stocker R., Keaney J.F. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 2004, 84:1381-1478.
145. Taatjes D.J., Wadsworth M.P., Schneider D.J., Sobel B.E. Improved quantitative characterization of atherosclerotic plaque composition with immunohistochemistry, confocal fluorescence microscopy, and computer-assisted image analysis. Histochem. Cell Biol. 2000, 113:161-173.
146. Tailleux A., Torpier G., Bonnefont-Rousselot D., Lestavel S., Lemdani M., Caudeville B., Furman C., Foricher R., Gardes-Albert M., Lesieur D., Rolando C., Teissier E., Fruchart J.C., Clavey V., Fievet C., Duriez P. Daily melatonin supplementation in mice increases atherosclerosis in proximal aorta. Biochem. Biophys. Res. Commun. 2002, 293:1114-1123.
147. Tailleux A., Gozzo A., Torpier G., Martin-Nizard F., Bonnefont-Rousselot D., Lemdani M., Furman C., Foricher R., Chevé G., Yous S., Micard F., Bordet R., Gardes-Albert M., Lesieur D., Teissier E., Fruchart J.C., Fiévet C., Duriez P. Increased susceptibility of low-density lipoprotein to ex vivo oxidation in mice transgenic for human apolipoprotein B treated with 1 melatonin-related compound is not associated with atherosclerosis progression. J. Cardiovasc. Pharmacol. 2005, 46:241-249.
148. Tamminen M., Mottino G., Qiao J.H., Breslow J.L., Frank J.S. Ultrastructure of early lipid accumulation in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 1999, 19:847-853.
149. Tamura H., Nakamura Y., Narimatsu A., Yamagata Y., Takasaki A., Reiter R.J., Sugino N. Melatonin treatment in peri- and postmenopausal women elevates serum high-density lipoprotein cholesterol levels without influencing total cholesterol levels. J. Pineal Res. 2008, 45:101-105.
150. Tan D.-X., Chen L.-D., Poeggeler B., Manchester L.C., Reiter R.J. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr. J. 1993, 1:57-60.
151. Tan D.X., Pöeggeler B., Reiter R.J., Chen L.D., Chen S., Manchester L.C., Barlow-Walden L.R. The pineal hormone melatonin inhibits DNA-adduct formation induced by the chemical carcinogen safrole in vivo. Cancer Lett. 1993, 70:65-71.
152. Tan D.X., Hardeland R., Manchester L.C., Poeggeler B., Lopez-Burillo S., Mayo J.C., Sainz R.M., Reiter R.J. Mechanistic and comparative studies of melatonin and classic antioxidants in terms of their interactions with the ABTS cation radical. J. Pineal Res. 2003, 34:249-259.
153. Tan D.X., Manchester L.C., Terron M.P., Flores L.J., Reiter R.J. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species?. J. Pineal Res. 2007, 42:28-42.
154. Tan D.X., Manchester L.C., Fuentes-Broto L., Paredes S.D., Reiter R.J. Significance and application of melatonin in the regulation of brown adipose tissue metabolism: relation to human obesity. Obes. Rev. 2011, 12:167-188.
155. Tan D.X., Manchester L.C., Liu X., Rosales-Corral S.A., Acuna-Castroviejo D., Reiter R.J. Mitochondria and chloroplasts as the original sites of melatonin synthesis: a hypothesis related to melatonin's primary function and evolution in eukaryotes. J. Pineal Res. 2013, 54:127-138.
156. Tengattini S., Reiter R.J., Tan D.X., Terron M.P., Rodella L.F., Rezzani R. Cardiovascular diseases: protective effects of melatonin. J. Pineal Res. 2008, 44:16-25.
157. Ting K.N., Dunn W.R., Davies D.J., Sugden D., Delagrange P., Guardiola-Lemaitre B., Scalbert E., Wilson V.G. Studies on the vasoconstrictor action of melatonin and putative melatonin receptor ligands in the tail artery of juvenile Wistar rats. Br. J. Pharmacol. 1997, 122:1299-1306.
158. Toutouzas K., Synetos A., Nikolaou C., Tsiamis E., Tousoulis D., Stefanadis C. Matrix metalloproteinases and vulnerable atheromatous plaque. Curr. Top. Med. Chem. 2012, 12:1166-1180.
159. Tranfield E.M., Walker D.C. The ultrastructure of animal atherosclerosis: what has been done, and the electron microscopy advancements that could help scientists answer new biological questions. Micron 2013, 46:1-11.
160. Tranfield E.M., van Eeden S.F., Yateram K., Hoggm J.C., Walker D.C. Ultrastructural changes in atherosclerotic plaques following the instillation of airborne particulate matter into the lungs of rabbits. Can. J. Cardiol. 2010, 26:e258-e269.
161. Turrens J.F. Mitochondrial formation of reactive oxygen species. J. Physiol. 2003, 552:335-344.
162. van Zandvoort M., Engels W., Douma K., Beckers L., Oude Egbrink M., Daemen M., Slaaf D.W. Two-photon microscopy for imaging of the (atherosclerotic) vascular wall: a proof of concept study. J. Vasc. Res. 2004, 41:54-63.
163. Venegas C., García J.A., Escames G., Ortiz F., López A., Doerrier C., García-Corzo L., López L.C., Reiter R.J., Acuña-Castroviejo D. Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations. J. Pineal Res. 2012, 52:217-227.
164. Victor V.M., Apostolova N., Herance R., Hernandez-Mijares A., Rocha M. Oxidative stress and mitochondrial dysfunction in atherosclerosis: mitochondria-targeted antioxidants as potential therapy. Curr. Med. Chem. 2009, 16:4654-4667.
165. Virmani R., Kolodgie F.D., Burke A.P., Farb A., Schwartz S.M. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 2000, 20:1262-1275.
166. Vitalini S., Gardana C., Simonetti P., Fico G., Iriti M. Melatonin, melatonin isomers and stilbenes in Italian traditional grape products and their antiradical capacity. J. Pineal Res. 2013, 54:322-333.
167. Walters-Laporte E., Furman C., Fouquet S., Martin-Nizard F., Lestavel S., Gozzo A., Lesieur D., Fruchart J.C., Duriez P., Teissier E. A high concentration of melatonin inhibits in vitro LDL peroxidation but not oxidized LDL toxicity toward cultured endothelial cells. J. Cardiovasc. Pharmacol. 1998, 32:582-592.
168. Wang Y., Liu X., Wang W., Song W., Chen L., Fang Q., Yan X. The expression of inflammatory cytokines on the aorta endothelia are up-regulated in pinealectomized rats. Inflammation 2013, [Epub ahead of print].
169. Wong B.W., Meredith A., Lin D., McManus B.M. The biological role of inflammation in atherosclerosis. Can. J. Cardiol. 2012, 28:631-641.
170. Yamagishi S., Matsui T., Nakamura K. Atheroprotective properties of pigment epithelium-derived factor (PEDF) in cardiometabolic disorders. Curr. Pharm. Des. 2009, 15:1027-1033.
171. Yang Q., Scalbert E., Delagrange P., Vanhoutte P.M., O'Rourke S.T. Melatonin potentiates contractile responses to serotonin in isolated porcine coronary arteries. Am. J. Physiol. Heart Circ. Physiol. 2001, 280:H76-H82.
172. Yu E., Mercer J., Bennett M. Mitochondria in vascular disease. Cardiovasc. Res. 2012, 95:173-182.
173. Yuan H., Pang S.F. [125I]Iodomelatonin-binding sites in the pigeon brain: binding characteristics, regional distribution and diurnal variation. J. Endocrinol. 1991, 128:475-482.
174. Zhu H.Q., Cheng X.W., Xiao L.L., Jiang Z.K., Zhou Q., Gui S.Y., Wei W., Wang Y. Melatonin prevents oxidized low-density lipoprotein-induced increase of myosin light chain kinase activation and expression in HUVEC through ERK/MAPK signal transduction. J. Pineal Res. 2008, 45:328-334.
175. Zisapel N. Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting. Cell. Mol. Neurobiol. 2001, 21:605-616.
176. Zisapel N. Sleep and sleep disturbances: biological basis and clinical implications. Cell. Mol. Life Sci. 2007, 64:1174-1186.